InvestorsHub Logo
Followers 20
Posts 1031
Boards Moderated 0
Alias Born 10/17/2006

Re: XenaLives post# 120730

Tuesday, 09/19/2017 10:30:41 PM

Tuesday, September 19, 2017 10:30:41 PM

Post# of 458880
re: "He had similar expression for PRANA drug and trial. So not very reliable "

re:"That's not what I remember - can you back your claim up with the EXACT quote about PRANA, including how many people he was talking about?

We may recall an article from 2013

"Macfarlane said that the drug seems to have slowed the progression of the disease by about 30 percent in patients with mild Alzheimer’s compared to placebo"

MacPharlane's also makes a more upbeat remark was about a single patient out of the whole group who managed to show some improvement as a "preliminary response" . This is what certain people seem to remember while forgetting about his objective factual account quoted above describing mediocre (ie not very good) PRANA results overall, in the same article.

Macpharlane is reliable. Just how the press chooses to adjust emphasis in a story for maximum public readership appeal is sometimes unreliable in regard to presenting reality. Will they write: "Ten million people bought lottery tickets but didn't win." or "Poor man wins fortune!".

"The article indirectly references Prana’s oral drug, called PBT2, and the IMAGINE trial, discussing the benefits that have been observed in a 57-year-old Alzheimer’s patient named Kelvin Lawler.

Further, Prana was pegged to the article with an image of its experimental 250 mg red pill and pill bottle with the name of the drug used in the accompanying video.

According to Associate professor Steve Macfarlane, who has been overseeing the trial at Melbourne’s Caulfield Hospital as part of the global study, the preliminary response by Lawler has been “incredible.” Macfarlane noted a clear improvement in Lawler’s memory, saying Lawler is a “poster child for success in clinical trials.”

The IMAGINE trial is a 12-month, double-blind study where patients are administered PBT2 once per day and tested once per month for any effect."

https://www.equities.com/news/prana-biotechnology-pran-continues-upward-on-alzheimer-s-disease-drug-news

There is no comparison, no parallel in past trials to what we are seeing now in regard to good results with Anavex 2-73

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News